

GRIFOLS CORPORATE STATEMENT ON THE NOVEL CORONAVIRUS

March 4, 2020

Employee safety is our priority

As the situation with the novel coronavirus rapidly evolves, Grifols is taking measures in line with recommendations from the WHO to help ensure the safety of our employees, while it has also made its expertise in plasma available to health authorities since the outbreak began.

Since February 24, Grifols has canceled all international business travel unless strictly necessary. Business will be conducted through video conferencing and other technologies through March 31, when the situation will be reviewed.

Ensuring product supply and safety

Aware that our products and services are important to patients and healthcare providers around the world, we can confirm at this moment there are currently no supply delays or interruptions as a result of the novel coronavirus.

Every single donation at Grifols goes through exhaustive analyses to ensure it meets our strict requirements. However, out of an abundance of caution, we are implementing additional protocols in our donor centers to ensure donor eligibility. Furthermore, our plasma product manufacturing process contains dedicated steps for viral inactivation that ensure high safety margins against this type of virus.

Given the exceptional circumstances, all relevant knowledge matters

Grifols has deep expertise and technology in the use of virally inactivated convalescent plasma – plasma obtained from recovering patients – to develop potential anti-viral immunoglobulin treatments. This expertise has already been shared with our partner-to-be in China, Shanghai RAAS, and the Chinese public health system. We are also making it available to other international public health authorities. At the same time, Grifols is accelerating the development of screening and testing methods for the detection of the novel coronavirus.

Grifols is closely monitoring developments. We will continue to take actions, in consultation with advice from the WHO and associated government agencies, to protect our employees, ensure our medicines and products reach those who need them, and do what we can to help combat the coronavirus.

*For additional information, please see the [statement](https://www.pptaglobal.org/media-and-information/ppta-statements/1055-2019-novel-coronavirus-2019-ncov-and-plasma-protein-therapies) from the Plasma Protein Therapeutics Association (PPTA).
<https://www.pptaglobal.org/media-and-information/ppta-statements/1055-2019-novel-coronavirus-2019-ncov-and-plasma-protein-therapies>*

GRIFOLS